Vaxart Stock Is Surging As Its Oral COVID-19 Vaccine Can Potentially Trigger Immunity Against Variants

  • Vaxart Inc VXRT has announced new data from the Phase 1 trial evaluating its oral COVID-19 vaccine candidate, dubbed as VXA-CoV2-1.
  • Data obtained showed substantial CD8+ T-cell responses against SARS-Cov-2 and showed cross-reactivity against diverse endemic coronaviruses such as 229E, NL63, HKU1, and OC43.   
  • In a comparative experiment, Phase 1 study data was compared to T-cell responses from volunteers subsequently vaccinated with the Moderna Inc’s MRNA or Pfizer Inc PFEBioNTech SE BNTX vaccines, indicating the mRNA vaccines induced fewer T-cell responses.
  • “The strength of T-cell responses against both S and N proteins, which we targeted, leads us to believe that VXA-CoV2-1 offers a promising solution to variants,” said Dr. Sean Tucker, chief scientific officer at Vaxart.
  • Price Action: VXRT shares up 17.5% at $9.42 in the premarket session on the last check Tuesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareSmall CapGeneralBriefsCOVID-19 VaccinePhase 1 Trial
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!